Penumbra Inc (PEN)
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
📉 **NEGATIVE** • Medium confidence analysis (76%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (5%) **Content type:** Clinical